



Biofit

FOSTERING
INNOVATION
& TRANSFER

A 360° approach to source
early-stage innovations in Life Sciences

PROGRAMME

6th
edition

& 28th
29th
NOVEMBER
2017



Strasbourg


France

 #BioFIT
@BIOFIT_EVENT

Organised by:  **eurasanté**
Invest for Success



 **Alsace
BioValley**

With the support of:  **connectus**
LIFE SCIENCES

WELCOME TO BIOFIT 2017

«Year after year, BioFIT has emerged as the leading partnering event in Europe to source early-stage innovations and collaborative research capacities in Life Sciences.

We are pleased to see the development of the event as a marketplace for pre-seed, seed and Series A investment in Life Sciences over recent years.

During this 6th edition of BioFIT, you will be more than 1,000 delegates from 30 countries representing large companies, medium-sized businesses, start-ups as well as tech transfer organisations, academics and investors. We look forward to seeing many high-potential collaborations generated during the convention.

Don't miss also this edition's conferences, with international high-level speakers, which present the perfect opportunity to gain insight and discover the latest industry trends.

Now it's time for us to let you take the control of what is your event. We wish you productive and enjoyable two days, with a variety of meetings and partnership opportunities.»

Etienne Vervaecke,
General Commissioner of BioFIT



1,200
DELEGATES



800
ORGANISATIONS



30+
COUNTRIES
REPRESENTED



35+
ONE-TO-ONE MEETINGS
PER PARTICIPANT
OVER 2 DAYS



800
LICENSING
OPPORTUNITIES
(in 2016)

80

speakers

15

conferences
and roundtable
discussions

100

exhibitors

TABLE OF CONTENTS

The Sponsors	4
The Organisers.....	6
The Steering Committee	7

ONE-TO-ONE MEETINGS

Partnering.....	8
Who will you meet?.....	9

AGENDA

Day 1	10
Day 2	11

CONFERENCES AND ROUNDTABLE DISCUSSIONS

PLENARY SESSION	13
TRACK 1	14
New players involved in innovation in the health sector	
TRACK 2	18
Nurturing and licensing early-stage assets	
TRACK 3.....	22
Bioentrepreneur's challenges at pre-seed, seed & Series A stages	

HOSTED EVENTS

Open Data Challenge	25
R&D Dating for Animal Health and Innovation	26
Medalis Conference	28

PRESENTATION SESSIONS

Start-up Slams	30
Start-up Slams' Agenda	32
Licensing Opportunity Presentations	34
Licensing Opportunity Presentations' Agenda	35

EXHIBITION

Exhibitor List	38
Floor Plan	39

The Supporters & Partners	67
---------------------------------	----

THE SPONSORS

GOLD SPONSOR



BRONZE SPONSORS



CONTRIBUTING SPONSORS



INSTITUTIONAL PARTNERS




Cultura RM Exclusive/Edwin Jimenez/Gettyimages

Empowering Life

Sanofi.com

SANOFI  Empowering Life



*Extraordinary medicine
requires extraordinary science.*

That's why we are committed to discovering
and developing personalised medicines and
targeted diagnostic tests to help people live
better, longer lives.



THE ORGANISERS

EURASANTÉ

Eurasanté is an incubator, a technology transfer facilitator and a leading cluster in the fields of biotech, nutrition and healthcare in the Northern France region. It assists French and foreign companies, entrepreneurs, scientists and clinicians with their innovation and development projects.

The regional network includes more than 1,000 companies working in Life Sciences and Healthcare. It benefits from an exceptional location in the heart of Europe (near Paris, London and Brussels). The Life Sciences sector in the Northern France region gathers a total of 28,000 employees. Eurasanté also promotes the Eurasanté Bio-business Park which hosts 7 hospitals, 4 universities, 7 specialised schools, more than 150 companies and 50 laboratories.

In addition, Eurasanté organises 4 international partnering events annually, which aim to increase and improve interactions between academia and industry and encourage additional innovative sector collaborations: BioFIT, MedFIT, NutrEvent and AgeingFit.

www.lille.eurasante.com @Eurasante



THE NHL CLUSTER

The Nutrition Health Longevity (NHL) Cluster is a dynamic network focusing on the main issues at the crossroads of health, biotechnology and nutrition.

The NHL Cluster aims to federate public and private partners around R&D projects, which lead to innovative products in the fields of nutrition and health.

The NHL Cluster's activity is centred around the prevention and treatment of life-style related diseases, such as metabolic and cardiovascular pathologies, neurodegenerative and inflammatory bowel diseases. Its objective is to gather and support players from the health and food sectors in the design, the development and financing of their future products and processes.

www.nhl-cluster.com @PoleNSL



ALSACE BIOVALLEY

As a French world-class cluster dedicated to therapeutic innovations, Alsace BioValley is the one-stop contact to optimise any R&D development or business project in Europe, both in drug development and medical technologies. Located in Eastern France, part of the famous French-German-Swiss BioValley and with a unique concentration of international life sciences & healthcare players, Alsace BioValley helps any Life Sciences & Healthcare companies or academics interested in new projects and partnerships in Europe to search outstanding scientific or industrial partners to develop very innovative R&D projects, to find the best innovative technology, patent or scientific expertise, or set up and locate in Eastern France. Alsace BioValley has also agreements with BioWin (Wallonia), CQDM (Quebec), JBA (Japan Bioindustry Association), Biopro (Germany) and Basel Area (Switzerland).

www.alsace-biovalley.com @AlsaceBiovalley



THE STEERING COMMITTEE

PHARMA, BIOTECH



Cédric Barriere
DIRECTOR, EXTERNAL INNOVATION
ONCOLOGY, EXTERNAL SCIENCE
AND PARTNERING, **SANOFI** [FR]



Maria Bobadilla
SENIOR DIRECTOR, EXTENDING
INNOVATION NETWORK,
ROCHE [CH]



Adrian Carter
CORPORATE VICE PRESIDENT AND
GLOBAL HEAD OF DISCOVERY
RESEARCH COORDINATION,
BOEHRINGER INGELHEIM [DE]



Sami Chtourou
DIRECTOR OF TECHNOLOGY
PLATFORMS AND INNOVATION,
LFB [FR]



Florence Dal Degan
R&D INNOVATION SOURCING
DIRECTOR, **NOVO NORDISK** [DK]



Guy Helin
CEO, **SYNGULON** [BE]



Stephan Lensky
CHIEF OPERATING AND CHIEF
BUSINESS OFFICE, **EPIMAB**
BIO THERAPEUTICS [CN]



Sabrina Lesage
STRATEGIC ALLIANCES MANAGER,
PFIZER [FR]



Pascal Raoul
SCIENTIFIC AND INNOVATION
DIRECTOR, **CEVA** [FR]



Frédéric Scaerou
DIRECTOR, SCIENTIFIC
AFFAIRS ONCOLOGY,
IPSEN INNOVATION [FR]



Nadine Weisslinger-Darmon
MEDICAL DIRECTOR SPECIALTY
PRODUCTS, CLINICAL RESEARCH
AND ACADEMIC ALLIANCES, **GSK** [FR]

ACADEMIA, TTOs



Hervé Ansanay
OPERATIONS DIRECTOR,
SATT AXLR [FR]



Garold Breit
DIRECTOR, TECHNOLOGY
BUSINESS DEVELOPMENT,
CITY OF CHARLESTON [USA]



Nicolas Carboni
PRESIDENT, **SATT CONECTUS**
ALSACE [FR]



Jean-Luc Chagnaud
HEALTHCARE BUSINESS
DEVELOPMENT MANAGER
& INTELLECTUAL PROPERTY
MANAGER, **AQUITAINE SCIENCE**
TRANSFERT [FR]



Lilla Farkas
HEAD OF THE OFFICE OF THE
MANAGING DIRECTOR, RESEARCH
COORDINATOR, **MPI-CBG**,
MAX PLANCK INSTITUTE OF
MOLECULAR CELL BIOLOGY AND
GENETICS [DE]



Matthieu Fisichella
LIFE SCIENCES EXPERT,
SATT NORD [FR]



Esther Lange
INDUSTRY LIAISON MANAGER,
ASCENION [DE]

ASSOCIATIONS, CLUSTERS, INVESTORS & LAW FIRMS



Claude-Alain Cudennec
GENERAL DIRECTOR, **AFSSI** -
THE FRENCH ASSOCIATION OF
OUTSOURCING AND INNOVATIVE
COMPANIES [FR]



Barbara Freischem
MANAGING DIRECTOR, **EBC** -
EUROPEAN BIOPHARMACEUTICAL
ENTERPRISES [BE]



Jean-Louis Hunault
PRESIDENT, **SIMV** - **THE FRENCH**
ASSOCIATION OF THE ANIMAL
HEALTH INDUSTRY [FR]



Sara Nunez-Garcia
PRINCIPAL,
SOFINNOVA PARTNERS [FR]



Marco Pintore
GENERAL MANAGER,
ALSACE BIOVALLEY [FR]



Christian Policard
MEMBER OF THE BOARD,
CHAIRMAN OF THE BUSINESS
DEVELOPMENT SUB-COMMITTEE,
FRANCE BIOTECH [FR]



Emilie Royere
DIRECTOR, **EUROBIOMED** [FR]




Cécile Theard-Jallu
PARTNER ATTORNEY, **DE GAULLE**
FLEURANCE & ASSOCIÉS [FR]



Etienne Vervaecke
GENERAL MANAGER,
EURASANTE & NHL CLUSTER [FR]

PARTNERING

*48 hours to meet your future project partners,
accelerate innovation and get financed*



30% TTOs, Research institutions, Academics



20% Pharma & Diagnostic companies



20% Emerging Biotech companies



15% Preclinical CROs



10% Pre-seed, seed and Series A investors



5% Professional services, consulting and law firms

The partnering platform at BioFIT is powered by **partneringONE[®]**

a service of **EBD GROUP**

**Any question? The BioFIT team at the Partnering desk
(Exhibition hall) will be happy to assist you.**

CHECK THE FLOOR PLAN PAGE 39

WHO WILL YOU MEET?

**1,200 +
key actors**

INCLUDING:

Astellas Pharma, Basilea Pharmaceutica International, Bayer, Bayer Animal Health, Boehringer Ingelheim, Boehringer Ingelheim Animal Health, Ceva, Daiichi Sankyo, Evotec, Ferring Pharmaceuticals, GSK - GlaxoSmithKline, Ipsen Innovation, Johnson & Johnson Innovation, Kissei America, Kyorin Pharmaceutical, Kyowa Hakko Kirin, Laboratorios Rubio, LFB, Lilly, Merck, MSD, MSD Animal Health, Novo Nordisk, Pfizer, Roche, Sanofi, Servier, Syngulon, Takeda, TiGenix, Trianni, Vetoquinol, Virbac, Zoetis, Ascension, CNRS, EMBLEM, FIST, Imperial Innovations, LifeArc, Max Planck Institute, SATT Network, University of Birmingham, University of Cambridge, VIB, Broadview Ventures, Edmond de Rothschild Investment, Fund+, High-Tech Gründerfonds, Merck Ventures, Novartis Venture Fund, Sofinnova Partners, Thiel Capital, Truffle Capital, TVM Capital

**From 30 countries
around the world**

INCLUDING:



Austria



Belgium



Canada



China



Czech Republic



Denmark



Finland



France



Germany



Greece



Iceland



Ireland



Israel



Italy



Japan



Lithuania



Malaysia



Netherlands



Norway



Poland



Portugal



Singapore



South Korea



Spain



Sweden



Switzerland



Ukraine




United Kingdom



United States


AGENDA DAY ONE

Tuesday 28th November 2017

8.30 am 9.30 am	WELCOME COFFEE				
	Conferences and roundtable discussions	Presentation sessions	Hosted Event 	Partnering	
9.30 am 11.00 am	MADRID 4 ROOM Shared risk or competition for emerging assets: How can we optimise pharma-VC relationships?	MADRID 3 ROOM How can collaborations in rare diseases be an asset in a highly competitive and fast moving market?	INNOV AREA EXHIBITION HALL Licensing Opportunity Presentations Cancerology Osteo-Articular	ROME 5 ROOM Translational research at Medalis: From lab to biotech	Biofit One-to-one meetings & R&D dating for animal health and innovation
11.00 am 11.30 am	NETWORKING BREAK				
11.30 am 1.00 pm	PLENARY SESSION How can we overcome the shortage of bioentrepreneurs in Europe? CURIE ROOM - 1 st FLOOR				
1.00 pm 2.30 pm	LUNCH				
2.30 pm 4.00 pm	MADRID 4 ROOM Exploring the growing relationship between pharma, digital health companies and data providers	MADRID 3 ROOM Assessing the opportunity for licensing early-stage projects	INNOV AREA EXHIBITION HALL Start-up Slams Vascular/Metabolic Op2Lysis Emosis Cardior Pharmaceuticals AptamiR Therapeutics Vaccinology / Virology ViRelieve Vaxinano ParImmune	ROME 5 ROOM Early projects, early opportunity: Find your match	Biofit One-to-one meetings & R&D dating for animal health and innovation
4.00 pm 4.30 pm	NETWORKING BREAK				
4.30 pm 6.00 pm	MADRID 4 ROOM How are focused therapeutic funds becoming increasingly important at pre-seed, seed and series A stages?	MADRID 3 ROOM Workshop: A closer look at early-stage collaborations in the UK	INNOV AREA EXHIBITION HALL Licensing Opportunity Presentations Cancerology Osteo-Articular	ROME 5 ROOM Nature and nurture of an Academic drug discovery Centre	Biofit One-to-one meetings & R&D dating for animal health and innovation
6.30 pm	BIOPARTY ETOILE ROOM 1st FLOOR				

AGENDA DAY TWO

Wednesday 29th November 2017

8.30 am 9.00 am	WELCOME COFFEE			
	Conferences and roundtable discussions	Presentation sessions	Partnering	
9.00 am 10.30 am	MADRID 4 ROOM How to keep the founding scientists committed?	MADRID 3 ROOM How are collaborations key to improve innovation in metabolic diseases?	INNOV AREA EXHIBITION HALL Start-up Slams Oncology/Immuno-Onco STipe Therapeutics TheraNovir Elthera Chromalys	 One-to-one meetings
10.30 am 11.00 am	NETWORKING BREAK			
11.00 am 12.30 pm	MADRID 4 ROOM Where will European pre-seed, seed and Series A investment go in 2018?	MADRID 3 ROOM How can animal and human innovation / applications be mutually beneficial?	INNOV AREA EXHIBITION HALL Licensing Opportunity Presentations Neurology Vascular/Metabolic	
12.30 pm 2.00 pm	LUNCH			
2.00 pm 3.30 pm	MADRID 4 ROOM Are venture philanthropy and trusts emerging in the initial stages of funding?	MADRID 3 ROOM How can TTOs increase their role in the early development of spin-offs?	INNOV AREA EXHIBITION HALL Start-up Slams Research tools/ Therapeutic delivery Mecachips DyNABind SimplicityBio Renovas Ageing / Pain Innopen PRAGMA Therapeutics Reminiscences	& <

- Track 1: New players involved in innovation in the health sector
- Track 2: Nurturing and licensing early-stage assets
- Track 3: Bioentrepreneurs' challenges at pre-seed, seed and Series A stages

FOR MANY, AN ACTIVE LIFE
STOPS FAR TOO EARLY | OUR SCIENTISTS
WON'T ACCEPT THAT



By 2050 the world's population over 60 will have doubled to two billion, making age-related illness an even greater challenge for society. That's why we're seeking to help people stay healthier and more active in later life, be it through more targeted treatments for cancer and cardiovascular conditions,

solutions for eye diseases, or ways to keep those with arthritis moving. Because life shouldn't stop at 60 – not by any means. To find out how our innovations are helping to change lives for the better, visit www.bayer.com/ari1901.



Science For A Better Life

Johnson & Johnson INNOVATION

BECAUSE A GREAT IDEA
CAN COME FROM ANYWHERE

MAKE *the* CONNECTION

Johnson & Johnson Innovation Centres

A flexible approach to advancing early-stage innovation

Johnson & Johnson Innovation seeks to find the best science and technology partners, no matter where they are, to solve the greatest unmet needs of our time. Positioned at the heart of the world's most creative science hubs, we take a collaborative approach to partnering to advance early-stage innovation.

The next breakthrough idea can come from anywhere. Maybe it will come from you. Together we can transform ideas into healthcare solutions that change lives.

[@njinnovation](https://twitter.com/jnjinnovation)

www.jnjinnovation.com



©Johnson & Johnson Innovation LLC 2017.

CONFERENCES AND ROUNDTABLE DISCUSSIONS

28th Nov. 11.30 am - 1.00 pm | CURIE ROOM



MODERATOR

John Hodgson

DATA EDITOR, INFORMA

How can we overcome the shortage of bioentrepreneurs in Europe?

Europe is currently benefiting from a unique level of academic research and access to equity investment has also improved. Despite this, Europe is still lacking bioentrepreneurs. How can we attract entrepreneurs in Life Sciences? How to convince talented scientists to become entrepreneurs? Can the support from technology transfer offices, incubators and early investors provide sufficient mentorship and a wide enough network?

David Wehner

MANAGING DIRECTOR,
VENNEOS

Toby Reid

MANAGING DIRECTOR,
BIOCITY

Alain Wagner

RESEARCH DIRECTOR,
CNRS

Valentin Lubbe

PROGRAM MANAGER,
NORDIC MENTOR NETWORK
FOR ENTREPRENEURSHIP

Dick Hoogenberg

PARTNER, EY

Share your opinion on Twitter:



#BioFIT
@BIOFIT_EVENT

TRACK 1

New players involved in innovation in the health sector

Big data and health IT companies provide key expertise to potentially increase efficiency in the discovery, preclinical and clinical stages of development. What will their position and involvement be in the therapeutic innovation chain: Will they participate or lead? Examples of collaborations between biotech, pharma, IT companies and academic research will be highlighted. However, these new players don't only originate from the big data sector, they also come from various areas such as animal health or e-health.

28th Nov. 9.30 - 11.00 am | SALON MADRID 3 ROOM



MODERATOR

Wendy White

CHAIR, GLOBAL GENES

Fiona Nielsen

CEO, REPOSITIVE

Ward Capoen

SENIOR ANALYST,
V-BIO VENTURES

Olaf Ritzeler

SENIOR DIRECTOR, EXTERNAL
INNOVATION, RARE DISEASES,
SANOFI

Yann Hérault

DIRECTOR,
INSTITUT CLINIQUE
DE LA SOURIS

HOW CAN COLLABORATIONS IN RARE DISEASES BE AN ASSET IN A HIGHLY COMPETITIVE AND FAST MOVING MARKET?

How does the specific context of rare diseases (including fast-track status, low prevalence score) work in favour of long-lasting and shared partnerships between start-ups, pharma, academia, regulatory bodies and patient organisations?

28th Nov. 2.30 - 4.00 pm | SALON MADRID 4 ROOM



MODERATOR

Elsa Sotiriadis

CHIEF FUTURIST
& DIRECTOR, SOSV

Seamus Browne

HEAD OF INDUSTRY
PARTNERSHIPS, RCSI

Karlheinz Schmelig

MANAGING PARTNER,
CREATHOR VENTURES

Andrew Fried

LIFE SCIENCES EUROPE
DIRECTOR, IBM

Amer Fasihi

FOUNDER
CAROS CONNECT

EXPLORING THE GROWING RELATIONSHIP BETWEEN PHARMA, DIGITAL HEALTH COMPANIES AND DATA PROVIDERS

How can the availability of huge amounts of data, computational tools that can effectively analyse this data, and targeting therapeutics to specific populations can make this relationship grow faster for the benefit of innovation? With the right tools, do R&D professionals have the ability to rapidly mine data from the literature, regulatory documents, clinical trial data, electronic health records and other patient-centric information to help innovation move forward? To what extent will the growing place of big data companies offer them a leader role in the projects?

29th Nov. 9.00 - 10.30 am | SALON MADRID 3 ROOM



MODERATOR

**Farzad
Abdi-Dezfuli**

PARTNER, SARSIA SEED
MANAGEMENT AS

Grit Zahn

HEAD OF RESEARCH,
ETERNYGEN

Philippe Froguel

PROFESSOR OF GENOMIC MEDICINE,
IMPERIAL COLLEGE LONDON,
PROFESSOR OF ENDOCRINOLOGY,
LILLE UNIVERSITY HOSPITAL

Florence Dal Degan

R&D INNOVATION SOURCING
DIRECTOR, NOVO NORDISK

HOW CAN COLLABORATIONS KEY TO IMPROVE INNOVATION IN METABOLIC DISEASES?

Examples of successful collaborations to improve innovation in metabolic diseases. Through the presentation of several case studies: We will discuss how collaborations are key to improving innovation in metabolic diseases. This session will feature one collaborative model, one innovative start-up project, and a successful academia/pharma collaboration.

29th Nov. 11.00 am - 12.30 pm | SALON MADRID 3 ROOM

MODERATOR

Pascal BretonPRESIDENT & CEO,
VITAMFERO **Rudiger Raue**ASSOCIATE DIRECTOR
EXTERNAL INNOVATION,
ZOETIS **Peter Opdam**DIRECTOR, BUSINESS
DEVELOPMENT EUROPE,
MSD ANIMAL HEALTH **Isabel Fidalgo Carvalho**CEO,
EQUIGERMINAL **Pascal Boireau**COORDINATOR,
DIM 1 HEALTH

HOW CAN ANIMAL AND HUMAN INNOVATION / APPLICATIONS BE MUTUALLY BENEFICIAL?

We will address innovation opportunities and pitfalls to be avoided when engaging in collaborations between human health players and animal health actors. Which are the conditions to be gathered to make innovation happen? Which types of collaborations can be put in place? What are the successful examples? What are the limits to these collaborations?



Working together for better health

At Boehringer Ingelheim we believe in forming durable partnerships to develop innovative new medicines in areas of high unmet need. Our relationships range from discovery research, development and technology collaborations to clinical and commercial partnerships and full-scale, long-term strategic alliances.

Innovative medicines for people and animals have for more than 130 years been what the research-driven pharmaceutical company Boehringer Ingelheim stands for. Boehringer Ingelheim is one of the pharmaceutical industry's top 20 companies and to this day remains family-owned. Day by day, some 50,000 employees create value through innovation for the three business areas human pharmaceuticals, animal health and biopharmaceutical contract manufacturing. In 2016, Boehringer Ingelheim achieved net sales of around 15.9 billion euros. With more than three billion euros, R&D expenditure corresponds to 19.6 per cent of net sales.

We invite you to find out more about partnering with us by visiting
<http://partnering.boehringer-ingelheim.com>

www.boehringer-ingelheim.com



INVENT WITH US

MSD BUSINESS DEVELOPMENT & LICENSING

MSD is inventing because the world still needs cures for cancer, Alzheimer's disease, HIV, and so many other causes of widespread suffering.

We believe that building strong partnerships is critical to solving these challenging diseases — to help people go on, unburdened, to experience, create and live their best lives.

Together we can invent for life.

Learn more at msd.com/licensing.

MSD
INVENTING FOR LIFE

MSD is known as Merck in the United States and Canada.
Copyright ©2017 Merck Sharp & Dohme, a subsidiary of Merck & Co., Inc. All rights reserved. 9-17

TRACK 2

Nurturing and licensing early-stage assets

Early-stage assets evolve in an ecosystem where TTOs, scientists and entrepreneurs are closely connected. This subject will focus on assessing opportunities in licensing early-stage projects, discussing the mentoring role of TTOs and exploring scientists' commitment. It aims to underline the difficulties for maturing early-stage assets. How can we transform science into business more frequently and efficiently?

28th Nov. 2.30 - 4.00 pm | SALON MADRID 3 ROOM



MODERATOR

Marta Catarino

TECH TRANSFER
DIRECTOR, **TECMINHO** 🇵🇹

Pascal Neuville

CEO, **DOMAIN
THERAPEUTICS** 🇫🇷

Johan Cardoen

MANAGING DIRECTOR,
VIB 🇧🇪

Georgia Gliki

SENIOR BUSINESS
MANAGER TECHNOLOGY
TRANSFER, **LIFEARC** 🇬🇧

Klaus Mendla

GLOBAL HEAD,
CNS BD & LICENSING,
BOEHRINGER INGELHEIM 🇩🇪

Beat Steffen

PRINCIPAL,
NOVARTIS VENTURE FUND 🇨🇭

ASSESSING THE OPPORTUNITY FOR LICENSING EARLY-STAGE PROJECTS

What factors should be considered whether to out-license a technology or develop it towards a start-up? At what stage should the decision be made whether to out-license or to spin out? How does the decision whether to license or spin-out impact the commercialisation or 'transfer' strategy? What are the assets that an academic could think about when considering whether to spin out?

29th Nov. 9.00 - 10.30 am | SALON MADRID 4 ROOM



MODERATOR

Eric Halioua

CEO, **PDC*LINE PHARMA** 🇧🇪

Davidson Ateh

CO-FOUNDER & CEO,
BIOMOTI 🇬🇧

Barbara Domayne-Hayman

CHAIR,
PURIDIFY 🇬🇧

Egil Hulgaard

SENIOR EXECUTIVE BUSINESS
DEVELOPMENT OFFICER,
**TECHNICAL UNIVERSITY OF
DENMARK** 🇩🇰

Sascha Berger

PRINCIPAL, **TVM LIFE
SCIENCE MANAGEMENT** 🇩🇪

Tony Hickson

MANAGING DIRECTOR,
IMPERIAL INNOVATIONS 🇬🇧

How to keep the founding scientists committed?

To what extent should the scientist manage the future of the spin off? What is their role within a new professional management team? Can we impose on a scientist the role of being a CEO? What are the pro's and con's of the Professor becoming the CEO of his own spin-off? What needs to be considered when forming a company and what does that mean for the founding scientist?

29th Nov. 2.00 - 3.30 pm | SALON MADRID 3 ROOM



MODERATOR

David Coleman

HEAD OF SPIN-OUT COMPANIES,
ALTA INNOVATIONS 🇬🇧

Tami Raz

CEO, **HADASIT, TECHNOLOGY
TRANSFER COMPANY OF HADASSAH
MEDICAL ORGANIZATION** 🇮🇱

Duncan Holmes

EUROPEAN HEAD, DISCOVERY
PARTNERSHIPS WITH ACADEMIA,
GLAXOSMITHKLINE 🇬🇧

Mike Karim

CEO, **OXFORD ENDOVASCULAR** 🇬🇧

Serge Pampfer

MANAGING DIRECTOR,
WBC INCUBATOR 🇩🇪

How can TTOS increase their role in the early development of spin-offs?

Building the management team and completing initial financing rounds are key moments in the emergence of a new company. To what degree are TTOs involved in these two aspects of the project? How do they help newly-funded companies interact with their industrial and financial partners?



MODERATOR

John Mack

PHARMA PUNDIT &
PUBLISHER, PHARMA
MARKETING NEWS

Axel Polack

GENERAL PARTNER, JOINT
POLISH INVESTMENT FUND

Tamer Mohamed

CEO, ASPECT BIOSYSTEMS

Miguel Mulet

DIRECTOR OF STRATEGY &
CORPORATE DEVELOPMENT,
TIGENIX

Timothy Luker

SENIOR DIRECTOR, EMERGING
TECHNOLOGY & INNOVATION,
BUSINESS DEVELOPMENT,
ELI LILLY

HOW CAN WE DEFINE A MUTUALLY BENEFICIAL COLLABORATION BETWEEN AN ACADEMIC INSTITUTION AND A RESULTING SPIN-OFF?

How can we nurture a long-lasting collaboration between a university and its spin-offs? How do universities continue to provide the start-up with the support required? After the initial licensing deal, how often do academic institutions supply start-ups with additional licensing opportunities?

WORKSHOP



28th Nov. 4.30 - 6.00 pm | SALON MADRID 3 ROOM



MODERATOR

John Harris

CEO, OBN

Harry Destecroix

CEO, ZIYLO

Oliver Sexton

INVESTMENT MANAGER,
RAINBOW SEED FUND

Shawn Manning

CEO,
AKESIOS ASSOCIATES

Mak Khan

BUSINESS DEVELOPMENT &
TRANSACTIONS MANAGER,
CELL & GENE CATAPULT

Vibhuti Patel

TRANSLATIONAL RESEARCH MANAGER
BIOSCIENCE IMPACT TEAM,
UNIVERSITY OF CAMBRIDGE

A CLOSER LOOK AT EARLY-STAGE COLLABORATIONS IN THE UK

UK enjoys a very dynamic life sciences sector ensuring synergies between academic excellence, start-up pools and industrials.

Several illustrations of the dynamism of the Life Sciences industry in the UK will be highlighted during this workshop:

- ♦ Successful examples of collaborations UK academia/ European Industry or UK start-up/ European industry
- ♦ Cross border M&A to expand internationally
- ♦ Venture capital & early-stage funds in the UK

TRACK 3

Bioentrepreneurs' challenges at pre-seed, seed & Series A stages

The right mindset, a solid presentation and business model are not the only requirements that bioentrepreneurs must fulfil at pre-seed, seed and Series A stages. What have been the expectations of project maturity from investors in 2017? How often are new types of early-stage investors involved in financing rounds (including philanthropic and specialised ventures)? How does the angels/seed investors relationship work? Are there increasing interactions and partnerships between pharma and VCs at these initial stages?

28th Nov. 9.30 - 11.00 am | SALON MADRID 4 ROOM



MODERATOR

Michael Nowak

MANAGING PARTNER,
NOWAK VENTURES

Lucas de Breed

DIRECTOR, INKEF CAPITAL

Detlev Mennerich

INVESTMENT MANAGER,
BOEHRINGER INGELHEIM VENTURES

Timothy Luker

SENIOR DIRECTOR, EMERGING TECHNOLOGY & INNOVATION, BUSINESS DEVELOPMENT, ELI LILLY

Nathalie ter Wengel

EUROPEAN HEAD EXTERNAL R&D AND INNOVATION, PFIZER

Frédéric Legros

COO, DYNACURE

SHARED RISK OR COMPETITION FOR EMERGING ASSETS: HOW CAN WE OPTIMISE PHARMA-VC RELATIONSHIPS?

What are the consequences of the increasing interactions and partnerships between pharma and VCs at the initial stages of pre-seed, seed and Series A? What is the role of Corporate VCs in this context?

28th Nov. 4.30 - 6.00 pm | SALON MADRID 4 ROOM



MODERATOR

Fabrice Arousseau

CEO, PPRS RESEARCH

James Peyer

MANAGING PARTNER,
APOLLO VENTURES

Christian Tidona

MANAGING PARTNER & FOUNDER,
BIOMED X

Michael Midmer

CEO, ZUCARA THERAPEUTICS

Jakob Loven

PARTNER, NEXTECH INVEST

Philippe Pouletty

FOUNDER, TRUFFLE CAPITAL

HOW ARE FOCUSED THERAPEUTIC FUNDS BECOMING INCREASINGLY IMPORTANT AT PRE-SEED, SEED AND SERIES A STAGES?

What do these therapeutic funds bring to the companies and community of investors in terms of quality of expertise and specific network opportunities? Does the presence of focused therapeutic funding in the early stages ease the co-investment of more generalist funds?

29th Nov. 11.00 am - 12.30 pm | SALON MADRID 4 ROOM



MODERATOR

Evelyne Nguyen

CEO, ANM PARTNERS

Holger Reithinger

GENERAL PARTNER, FORBION CAPITAL PARTNERS

Hakan Goker

SENIOR INVESTMENT DIRECTOR,
MERCK VENTURES

Frank Hensel

SENIOR INVESTMENT MANAGER,
HIGH-TECH GRÜNDERFONDS

Sofia Ioannidou

INVESTMENT DIRECTOR,
EDMOND DE ROTHSCHILD INVESTMENT PARTNERS

WHERE WILL EUROPEAN PRE-SEED, SEED AND SERIES A INVESTMENT GO IN 2018?

What is the state of pre-seed, seed and Series A funding in Europe? What are the investment opportunities to watch for in 2018? What are the models, therapeutic area or innovative techniques to highlight when looking for financing? Can we expect a rise in pre-seed and seed money in Europe for 2018? What are the expectations for project maturity from investors in 2017?



MODERATOR

Paul Hermant

PARTNER, BIRD & BIRD

ARE VENTURE PHILANTHROPY AND TRUST EMERGING IN THE INITIAL STAGES OF FUNDING?

Christopher de Souza

DIRECTOR,
BROADVIEW VENTURES

Andreas Schmidt

CO-FOUNDER,
AYOXXA BIOSYSTEMS

Chris Greenwood

HEAD OF INVESTOR
RELATIONS, ESPERARE

Kayar Raghavan

ANGEL INVESTOR

What non-profit and non-dilutive sources of funding are available? Are these new actors equally active at maturation, pre-seed and seed stages? What potential leverage to accessing grants and other non-dilutive sources of funding does venture philanthropy offer to newly founded companies?



INNOVATIVE COMPANY IN TREATMENT AND DIAGNOSIS OF METABOLIC & INFLAMMATORY DISEASES

Connect together

www.genfit.com

contact@genfit.com




GENFIT



genfit_pharma

HOSTED EVENT BY



Challenge OPEN DATA

The Open Data Challenge is a call for projects that encourages open innovation initiatives between companies and public institutions facing digital challenges and SMEs which provide innovative technologies. Launched during summer 2017, the first phase of this project ended in September 2017 with the selection of three companies for their innovative solutions aimed at resolving the EFS's (French Blood Agency) blood forecasting needs.

The selected companies competing for the challenge are Kaduceo, Open DataSoft and Open Health.



Award Ceremony | 28th Nov. 5.30 pm | BOOTH D7 (Exhibition Hall)

«EFS' participation at the Open Data Challenge was obvious considering the interesting theme and regarding the opportunity to collaborate with qualified start-ups. This initiative, centred on Open Data will allow us to enhance our ability to adapt to upcoming evolutions and therefore, be as efficient as possible.»

Eric Resch, Haemovigilance and distribution officer, EFS

«Through our Digital Launch Pad Program, launched 2 years ago, we have helped hundreds of companies to develop their business activities. An increasing number of our clients work in the health sector and we are providing them with the necessary data storage services. We are delighted to share the type of expertise at the Open Data Challenge.»

Guillaume Fillière, Digital Launchpad Programme Manager, OVH

Organised by:



In collaboration with:



In partnership with:



Financed by:



HOSTED EVENT BY  **Biofit**



BioFIT hosts the 3rd edition of the “R&D dating for Animal Health and Innovation”, initiated by the French association for the animal health industry (SIMV), on 28th and 29th November 2017 in Strasbourg.

Today, public-private and private-private partnerships are thought to be the needed leverage for innovation. Hence, the SIMV (the French association for the animal health industry) launched the “R&D dating for Animal Health and Innovation” which aims at initiating high-level exchanges between the research departments of the veterinary medicine and diagnostics industry and public research, as well as biotechnology companies (start-ups).

By enabling face-to-face encounters, the event will enhance the visibility of cutting-edge research in France and in Europe, encourage investments and lead to therapeutic innovation.

29th Nov. 11.00 am - 12.30 pm | SALON MADRID 3 ROOM

How can animal and human innovation/applications be mutually beneficial?

We will address innovation opportunities and pitfalls to be avoided when engaging in collaborations between human health players and animal health actors. Which are the conditions to be gathered to make innovation happen? Which types of collaborations can be put in place? What are the successful examples? What are the limits to these collaborations?

> See details page 16

MEET SIMV AT BOOTH C13

Organised by:



The OneHealth Company

FULL-VET CRO for Human & Pets Health

Comparative medicine studies of pets with natural diseases for the Biotech/ Pharma industry

Dogs & Cats with natural cancer or age-related diseases as predictive models of human diseases

Pilot & Pivotal studies with pets for the Vet industry
Pets suffering from age-related diseases

Web: <http://www.oncovet-clinical-research.com/>
Contact: mdubruque@oncovet-clinical-research.com



LEARNING
UNDERSTANDING
TREATING

TOGETHER



The Medalis drug research centre is a «Laboratory of Excellence» (Labex) created in July 2011 as part of the French «Investments for the Future» programme. It is a member of «Initiatives of excellence» (IDEX) in the University of Strasbourg. Its aim is to develop innovative drugs for the treatment of cancer or inflammation.

Medalis' strengths:

- ♦ A unique network of 200 researchers and PhDs from 11 research teams focused on chemistry and biology whose excellency has been certified by the national «Agency for Evaluation of Research and Universities», currently «Haut Conseil de l'Évaluation de la Recherche et de l'Enseignement Supérieur».
- ♦ State-of-the-art scientific equipment, such as platforms dedicated to virtual and microfluidic screening.
- ♦ A stimulating environment: Medalis is based in the heart of Europe, in Strasbourg, where the research institutes are internationally renowned for their achievements in the fields of pharmacology and biotechnology.

Medalis researchers have access to a highly competitive research environment provided by Strasbourg University and national research institutions like CNRS or INSERM. Moreover, Strasbourg University was awarded for the excellence of its supported projects (including Medalis) and has received an «Initiative of Excellence» funding from the French Investment for the Future Programme.

LABEX MEDALIS CONFERENCE PROGRAMME

SESSION 1

Translational research at Medalis: From lab to biotech

28th Nov. 9.30 - 11.00 am | ROME 5 ROOM

ImmuPharma, a successful pioneer in academic private intimate collaboration [Sylviane MULLER, Laboratory of Immunology and Therapeutic Chemistry UPR3572 CNRS, Director; Robert Zimmze, CEO ImmuPharma].

From the molecular dissection of signalling receptor transmembrane domains interaction in cancer [Dominique Bagnard, The Microenvironmental Niche in tumorigenesis and targeted therapy INSERM U1109, Group Head] to **PeptiMimesis**

Pharma [Marjorie Sidhoum, CEO].

From innovation in click chemistry [Alain Wagner, Laboratory of Design and Application of Bioactive Molecules, UMR7199 CNRS-Unistra, Group Head] to **Syndivia** [Sasha Koniev, CEO].

From the development of a molecular tool predicting cancer drug efficacy, [Justine Fritz, Former PhD in Dominique Bagnard group, MN3T lab] to **Adaptherapy** [Bertrand Loubaton, CEO].

SESSION 2

Early projects, early opportunity: Find your match

28th Nov. 2.30 - 4.00 pm | ROME 5 ROOM

Moderator: Jean-Christophe Peter [Scientific Manager, Labex Medalis]

Development of a PPI inhibitor of the CDK4/cyclin D complex for cancer treatment [Frédéric Bihel, Laboratory of therapeutic Innovation, UMR 7200 CNRS-Unistra].

Preclinical validation of the therapeutic potential of MTP-PlexA1 in demyelination disease [Fabien Biname, The Microenvironmental Niche in tumorigenesis and targeted therapy INSERM U1109].

Fluorospexin and Pain [Dominique Bonnet, Laboratory of therapeutic Innovation, UMR 7200 CNRS-Unistra, And Frédéric Simonin, GPCR, Pain and Inflammation, UMR 7242 CNRS-Unistra].

Peptide P140 and asthma: Preclinical evaluation in relevant mouse models [Nelly Frossard,

Laboratory of therapeutic Innovation, UMR 7200 CNRS-Unistra].

Neutraligands of CXCL12 [Marcel Hibert, Laboratory of therapeutic Innovation, UMR 7200 CNRS-Unistra].

Nanostructured Carriers for Intelligent siRNA co-delivery with anticancer drugs

[Antoine Kichler, Laboratory of Design and Application of Bioactive Molecules, UMR7199 CNRS-Unistra].

A global and rational approach to PPI modulation [Didier Rognan, Laboratory of therapeutic Innovation, UMR 7200 CNRS-Unistra].

MicroOmics: Deciphering cancer heterogeneity at the single cell multi-omic level [Sylvain Ursuegui, Laboratory of Design and Application of Bioactive Molecules, UMR7199 CNRS-Unistra].

SESSION 3

Nature and nurture of an academic drug discovery centre

28th Nov. 4.30 - 6.00 pm | ROME 5 ROOM

ROUND TABLE:

Moderator: Jean-Christophe Peter, Scientific Manager, Labex Medalis

- ♦ How developing a continuing research effort out of the box?
- ♦ How educating researchers at the interface of chemistry and biology?
- ♦ How involving industrial partners?
- ♦ The role of corporate sponsorship in such initiatives?

[Pierre Eftekhari, INOVIEM Scientifique - Serge Potier, University of Strasbourg - Jean Gagneux, CiRFC Foundation - Marcel Hibert, Faculty of Pharmacy - Stephane Jenn, NOVALIX - Pascal Neuville, Domain Therapeutics].

START-UP SLAMS

The Start-up Slams are presented by entrepreneurs who have created an innovative company (less than 5-year-old or to be created). During the presentations, the selected candidates will present their project to potential partners and investors who could support their company and receive feedback and advice (speed-mentoring) from a panel of experts.

AWARD CEREMONY 29th Nov. 3.30 pm | INNOV' AREA EXHIBITION HALL

The most innovative start-up will be rewarded
on Day 2 of BioFIT at 3.30 pm in the INNOV' AREA
in the exhibition hall.



DISCOVER THE MOST INNOVATIVE START-UPS IN THE FOLLOWING FIELDS:

20 start-ups, 1 prize

VASCULAR/METABOLIC	ONCOLOGY/ IMMUNO-ONCO	RESEARCH TOOLS/ THERAPEUTIC DELIVERY	VACCINOLOGY / VIROLOGY	AGEING / PAIN
Op2Lysis Cardior Pharmaceuticals Emosis AptamiR Therapeutics	STipe Therapeutics Theranovir Elthera Chromalys	Mecachips DyNAbind SimplicityBio Renovos	ViRelieve Vaxinano Par'Immune	Innopain PRAGMA Therapeutics Reminiscences

PANEL OF EXPERTS:

Maria Bobadilla

SENIOR DIRECTOR, EXTENDING
INNOVATION NETWORK,
ROCHE +

Esther Lange

INDUSTRY LIAISON
MANAGER, ASCENION 🇩🇪

Garold Breit

DIRECTOR, TECHNOLOGY
BUSINESS DEVELOPMENT,
CITY OF CHARLESTON 🇺🇸

Stephan Lensky

CHIEF OPERATING
& CHIEF BUSINESS OFFICE,
EPIMAB BIOTHERAPEUTICS +

Florence Dal Degan

R&D INNOVATION
SOURCING DIRECTOR,
NOVO NORDISK +

Cécile Theard-Jallu

PARTNER ATTORNEY,
DE GAULLE FLEURANCE
& ASSOCIÉS 🇫🇷

Joel Yao

ASSOCIATE,
SOFINNOVA PARTNERS 🇫🇷

Christopher de Souza

DIRECTOR,
BROADVIEW VENTURES 🇺🇸

AGENDA | START-UP SLAMS

28th Nov. 2.30 > 4.00 pm | INNOV' AREA



VASCULAR/ METABOLIC

Op2Lysis

Intracerebral Haemorrhage (ICH) or haemorrhagic stroke | O2L-001, first medical treatment of ICH | Intracerebral thrombolysis with minimally invasive surgery

Cardior Pharmaceuticals

Heart failure | Innovative RNA based therapeutics | Platform on noncoding RNA based therapeutics and diagnostics

Emosis

In vitro diagnostics | Haemostasis | International

AptamiR Therapeutics

Human obesity | Browning of adipocytes | MicroRNAs



VACCINOLOGY/ VIROLOGY

Vaxinano

Biotechnology | Nanoparticles | Vaccination

ViRelieve

Human Respiratory Infectious (HRI) | Antivirals | Protein-protein interactions (PPIs)

Par'Immune

Inflammation | Immunotherapy | Parasite subunit | Helminths

29th Nov. 9.00 > 10.30 am | INNOV' AREA



ONCOLOGY/IMMUNO-ONCO

STipe Therapeutics

Immune Oncology | Innate immune regulation | STING agonists

Elthera

Oncology | Antibody therapy | Novel target

Theranovir

Biomarkers | Anti-cancer antibodies | Anti-angiogenic and Checkpoint inhibitors

Chromalys

Radiotherapy | Tumor labelling | Nano & micro technology

29th Nov. 2.00 > 3.30 pm | INNOV' AREA



RESEARCH TOOLS/ THERAPEUTIC DELIVERY

Mecachips

In vitro cell biology | Elastic and soft culture plates | Physiological in vitro cell culture

DyNABind

Drug Discovery Technology | Small Molecule Drugs | Quality-controlled Libraries

SimplicityBio

Biomarker discovery | Diagnostic - Dx | Companion diagnostics - CDx

Renovos

Regenerative medicine | Orthopaedic biomaterials | Bone fracture healing



AGEING/PAIN

Innopain

Innovative Pharmacological Target | Protected NCEs | To replace opiates

PRAGMA Therapeutics

Sensorineural Hearing loss | mGlu7 receptor modulator | Small molecule

Reminiscences


Alzheimer's disease | Gut Microbiome | Therapeutic with companion diagnostic

LICENSING OPPORTUNITY PRESENTATIONS

The Licensing Opportunity Presentations are presented by TTOs, universities or related structures that have ready-to-be-licensed technologies.

The aim of this session is to foster alliances and business development opportunities on innovative projects stemming from academia.

DISCOVER THE LATEST INNOVATIONS IN THE FOLLOWING FIELDS:



AGENDA | LICENSING OPPORTUNITY PRESENTATIONS

28th Nov. 9.30 > 11.00 am | INNOV' AREA

MODERATOR **Shawn Manning** | CEO, AKESIOS ASSOCIATES 



CANCEROLOGY

Dermapol: Real time spectro-polarimetric optical biopsy

Melanoma | Diagnosis
Dermatology

Bifunctional cyclam based ligands for conjugations with targeting vectors and their ⁶⁴-Cu radiopharmaceuticals for PET imaging

Molecular imaging |
Radiopharmaceuticals |
Macrocyclic chelators

New chemical entities activating the AMPK pathway for the treatment of melanoma and other solid tumors

Melanoma | Cancer | Metformin

Selective inhibitors of 17 β -hydroxysteroid dehydrogenases

Estrogen | Cancer | Endometriosis



OSTEO-ARTICULAR

Ultrasound-based Motion capture of bones

Ultrasound-based motion capture |
Quantitative analysis of walking |
Prosthetic design, optimisation and evaluation

S-Tronic Vertebro: Cement injection device for Vertebroplasty

Remote control | Osteoporosis |
Cement injection

Implantable and nanoactive medical device for Osteo-articular regeneration

Osteo-articular regeneration |
Medical device | Combined
Advanced Therapeutic Medicinal Product



INFECTION/ IMMUNOLOGY

PCR Multiplex System for Fungal Diagnosis

PCR Multiplex | Fungal Infections | Diagnosis

SSC project - A preventive treatment for systemic sclerosis

Systemic sclerosis | Preventive treatment | Repurposing

Antiseptic, antithrombotic lock composition for catheters

Lock composition | Catheters | Antiseptic, antithrombotic solution

Leptospirosis rapid diagnostic test

Diagnosis | Leptospirosis | Sensitivity/sensibility

TMB3 - Development of a new and innovative antibiotic agent

Antibacterial agent | Multi-resistance mechanisms countering | Nosocomial infections-MRSA/VRSA/VRE diseases



DISCOVERY TOOLS / INFLAMMATION

Innovative Technology for in vivo Stabilization of Therapeutic Peptides

In vivo stabilization | Therapeutic peptides | Innovation

Production of cyclosporine-based micellar eye drops

Cyclosporin A | Eye drops | Ocular inflammation



NEUROLOGY

Method for prediction of clinical response to VNS therapy in epileptic patients

Neurology | Epilepsy | VNS therapy

BR297: Preventive and curative treatment of chemotherapy-induced neuropathic pain

Neurosteroid | Chemotherapy-induced neuropathic pain | Neuroprotection

New method to induce reprogramming of somatic cells into cortico-spinal neurons

Cortico-spinal neurons | Cellular reprogramming | Neurodegenerative disease

Repurposing Citalopram for Treatment of Machado-Joseph Disease

Neurodegenerative diseases | Drug repurposing | Spinocerebellar ataxia type 3



VASCULAR / METABOLIC

KABETE

Pancreatic islets | Type II diabetes | Regenerative Medicine

Shark - a suture-less vascular connector

Anastomosis connection tool | Surgical consumable | Time-saving

New biomarker for the prediction of the delayed brain stroke after subarachnoid haemorrhage

Brain Stroke | Predictive biomarker | Subarachnoid haemorrhage

Molecular diagnostics of genetic predisposition to acute coronary syndrome

Acute coronary syndrome | Predictive biomarker | Genetic susceptibility

EXHIBITOR LIST

3M PURIFICATION.....B3
ADIS.....F4

AFSSI

ASSOCIATION FRANÇAISE
DES SOCIÉTÉS DE SERVICES
ET D'INNOVATION.....F1-E4
CII/OA.....F1-E4
DRUGABUS.....F1-E4
ITEC SERVICES.....F1-E4
RD-BIOTECH.....F1-E4
SMALIS.....F1-E4

ALCAMI CORPORATION.....A1

ALSACE BIOVALLEY

ALSACE BIOVALLEY.....E2-D8
AÉRIAL.....E2-D8/1
BIONEXT.....E2-D8/2
CENTRE EUROPÉEN
D'ÉTUDE DU DIABÈTE.....E2-D8/8
CONFORMA FRANCE.....E2-D8/4
DYNACURE.....E2-D8/6
HARMONIC PHARMA.....E2-D8/7
KSLINK.....E2-D8/9
NANOTRANSMED.....E2-D8/3
PHENOMIN-ICS.....E2-D8/5

ARTES BIOTECHNOLOGY.....F2
ARVATO.....C8

ATLANPOLE BIOTHERAPIES

ATLANPOLE BIOTHERAPIES.....D3
BIOGENOUEST.....C11
ID2SANTÉ.....D3

BACCINEX SA.....A2
BACHEM.....C7

BIOTRIAL.....F3
CELL&CO BIOSERVICES.....A8
CIDEFC NANOMEDICINE.....B6
CITOXLAB.....E5
CYTENA GMBH.....E6
CZECHINVEST.....E3
DELPHARM BIOTECH.....B8
DOMAINEX.....A6
EATRIS.....C3B
ENTERPRISE LITHUANIA.....B10
E-PHY-SCIENCE.....B13
ERDYN.....B4
EU-JAPAN CENTRE FOR
INDUSTRIAL COOPERATION.....E7
FOK CLINICAL RESEARCH
GMBH.....A5
FINDMED.....D6
FUTURE WORLDS.....B11
GENOSAFE.....B12
IFREMER.....C1
INFICURE BIO.....E8
INOVEM SCIENTIFIC.....A3
KITOS BIOTECH, SRLS.....A7

LILLE NORTHERN FRANCE

BIOCLUSTER
EURASANTÉ.....D7
NUTRITION HEALTH.....D7
LONGEVITY CLUSTER.....E1-D7
AMYGEN.....D7
BOOST4HEALTH.....D7
GENOSCREEN.....D7
HCS PHARMA.....D7
INNOBIOCHIPS.....D7
SENCEIT.....D7

MACO PHARMA.....D2
MAGIE CHEMOSWED.....B5

MEDICALPS - THE HEALTH- TECH CLUSTER OF THE FRENCH ALPS

ARAYMONDILIFE.....D1-C9
ECRINS THERAPEUTICS
SERVICES.....D1-C9
RHEONOVA.....D1-C9

MICROSYNTH AG.....B2
NEURATRIS.....C3
NOVA BIOMEDICAL.....A4
OCR.....D9
OVH DIGITAL LAUNCH PAD.....E1
PHARMA LOGISTICS CLUB.....C12
PRECI PLATFORM.....D9
PORSOIT.....D4
PROGINASE.....C2

R&D DATING FOR

ANIMAL HEALTH AND INNOVATION - SIMV

SIMV - FRENCH
ASSOCIATION OF
ANIMAL.....C13
HEALTH INDUSTRY
INSTITUT CARNOT FRANCE
FUTURE EVEAGE.....C14
VET+ FOUNDATION,
SPANISH TECHNOLOGY
PLATFORM FOR ANIMAL
HEALTH.....D5

RÉSEAU SATT

AQUITAINE SCIENCE
TRANSFERT.....C6-B15
AXIR.....C6-B15
OUEST VALORISATION.....C6-B15
PULSAYS.....C6-B15
RÉSEAU SATT.....C6-B15

SATT CONECTUS.....C6-B15
SATT GRAND CENTRE.....C6-B15
SATT GRAND EST.....C6-B15
SATT NORD.....C6-B15
SATT SUD-EST.....C6-B15

SANTAKA VALLEY
ASSOCIATION.....B9
SCIENCE ME UP.....C10
SCIOIMICS - ENABLING
PRECISION MEDICINE.....C15
SOLADIS.....B7
SYNAGING SAS.....C4
VEOLIA WATER
TECHNOLOGIES.....D10
VIROSCAN3D.....B1
XPRESS BIOLOGICS.....B14

INNOV' AREA

VASCULAR | METABOLIC

APTAMIR THERAPEUTICS.....IA7
CARDIOR.....IA2
PHARMACEUTICALS.....IA6
EMOSS.....IA1
OP2LYSIS.....IA1

RESEARCH TOOLS

DYNABIND.....IA5
MECACHIPS.....IA9
RENOVOS.....IA11
SIMPLICITYBIO.....IA10

AGEING | PAIN

INNOPAIN.....IA12
PRAGMA
THERAPEUTICS.....IA16
REMINI-
SCIENCES.....IA20

VACCINOLOGY | VIROLOGY

PAR'IMMUNE.....IA4
VAXINANO.....IA8
VIRELIEVE.....IA3

ONCOLOGY | IMMUNO-ONCO

CHROMALYS.....IA19
ELUTHERA.....IA15
STIPE THERAPEUTICS.....IA17
THERANOVIR.....IA18

EXHIBITION PLAN



3M PURIFICATION

B3

Website: www.3m.com

3M Separation and Purification Sciences Division provides cutting edge separation and purification technology and products for biopharmaceutical companies involved in production of recombinant proteins, plasma fractionation products, vaccines and small molecule drugs. Using 3M's innovative material science platforms, we help companies optimize their processes, improve product safety and increase manufacturing efficiencies, thereby, improving lives everywhere as a trusted supplier of purification.

AÉRIAL

E2-D8/1

Website: www.aerial-crt.com

Aérial, Technology Resource Centre, offers services in R&D in the freeze-drying and radiation processing. Aerial's freeze-drying activities encompasses thermal characterization, formulation and development of freeze-drying recipes for pharma products. In radiation processing, Aerial's services cover validation of radiation sterilization and dosimetry for medical devices and pharma products and assessment of the impact product attributes with regard to standards requirements.

ALCAMI CORPORATION

A1

Website: www.alcaminow.com

Alcami's cGMP drug product manufacturing facilities support preclinical, clinical and commercial supply. Our Charleston, South Carolina, is focused on processing parenteral products while the Wilmington, North Carolina facility is dedicated to solid oral dose manufacture. Both are fully integrated with Alcami's packaging and distribution center. Two cGMP API facilities in Germantown, Wisconsin and Weert, Netherlands support Alcami's process development/scale-up and clinical and commercial supply for customers worldwide.

AMYLGEN

D7/1

Website: www.amylgen.com

Amylgen is a preclinical CRO dedicated to provide our clients a comprehensive platform of models of neurodegenerative diseases/neurological disorders and techniques for the in vivo screening and pre-clinical validation of new drugs or nutraceuticals.

ADIS

F4

Website: www.springer.com/gp/adis

AdisInsight is a database to support decision making in drug research and development. It's based on scientifically sound data, assessed and summarized by expert scientists. A single search in AdisInsight is equivalent to searching thousands of other sources. AdisInsight allows you to quickly see the 'big picture' of a drug/disease landscape, interlinking

Scientific and commercial information on drugs

- ♦ Clinical trials
- ♦ Deals, acquisitions, collaborations
- ♦ Safety data

AFSSI

F1-E4

Website: www.afssi.fr

The «Association Française des Sociétés de Services et d'Innovation (AFSSI)», French Association of Outsourcing and Innovative Companies in the field of Life Sciences was born in 2012 to gather companies established in France and providing R&D services to industrial or academic partners.

AFSSI represents over 130 companies involved in a dual business model, investing a significant part of their revenues in R&D to update and broaden their technology offering in order to run research programs.

ALSACE BIOVALLEY

E2-D8

Website: www.alsace-biovalley.com/en

As a French world-class cluster dedicated to therapeutic innovations, Alsace BioValley is the one-stop contact to optimize R&D development or business project in Europe, both in drug development and medical technologies. It is located in the famous French-German-Swiss BioValley with a unique concentration of international life sciences & healthcare players.

AQUITAINE SCIENCE TRANSFERT

C6-B15

Website: www.innovations-aquitaine.com

Aquitaine Science Transfert is the Technology Transfer Office for the south west of France, covering 5500 researchers and 135 laboratories. We represent the regional academic research labs: Bordeaux University, INSERM, CNRS, Pau University, Bordeaux Polytechnic Institute, ... Since our creation in July 2012, we have signed 34 license agreements, patented 243 technologies and created 13 startups. Health, wellness and medical devices represent a key business in which our company is highly involved.

ARAYMONDLIFE**D1-C9**Website: www.araymond-life.com

ARaymondLife is a French company, authorized as GMP EU pharmaceutical establishment since 2008, focused on the development and manufacture of solutions for the healthcare market. Specialized in plastic injection molding, ARaymondLife presents RayDylyo®, a RTU plastic push fit cap. Alternative to the aluminum cap, RayDylyo® is usable in isolators and RABS, for manual and automated capping. RayDylyo® exists in Ø20 and Ø 13mm, in bulk or nested, with or without the stopper pre-assembled in the cap.

ARVATO**C8**Website: www.arvato.com/en/industries/healthcare.html

Healthcare systems, sales channels and distribution chains undergo constant changes to ensure patients derive the greatest benefit from innovative and existing pharmaceuticals and medical products at the most reasonable costs. Arvato Healthcare develop tailor-made outsourcing solutions that actively include all stakeholders within the healthcare sector - from patients, doctors and pharmacists through to health insurance companies and manufacturers.

AXLR**C6-B15**Website: www.axlr.com

AxLR is a technology transfer acceleration company. Our specialty is helping innovative projects derived from academic research reach maturity and commercialization. We work with the main public-sector research laboratories in France's Mediterranean area in Occitanie, one of the most dynamic locations in Europe, with over 200 laboratories and some 12,000 researchers.

BACHEM**C7**Website: www.bachem.com

Bachem is a listed technology-based company focused on peptide chemistry. The company provides a comprehensive catalog of biochemicals available from stock and exclusive custom syntheses for research labs. A full range of services to the pharma and biotech industries complete the service portfolio. Headquartered in Switzerland with subsidiaries in Europe and the US, the group has a global reach and towards its customers, Bachem shows total commitment to quality, innovation and partnership.

ARTES BIOTECHNOLOGY**F2**Website: www.artes-biotechnology.com

Artes Biotechnology is a pharmaceutical contract research company specialized in microbial process development and technology transfer. We market the unique Metavax® (dHepB-VLP) technology in combination with yeast expression. This platform is applicable for large and multimeric antigens and able to create chimeric VLPs. In addition to genetic engineering, the company provides fermentation and downstream process development, analytical assay development and production cell line characterization.

ATLANPOLE BIOTHERAPIES**D3**Website: www.atlanpolebiotherapies.com

Atlanpole Biotherapies is truly involved in the medicine of tomorrow, with innovative areas of focus for the development of new therapies and the discovery of unexplored methodologies for human treatments. The projects of network, both academic and industrial, show the excellence of our expertise in personalized medicine.

It is a European Center Of Excellence in 4 domains:

- ♦ Immunobiotherapies
- ♦ Regenerative Medicine
- ♦ Radiopharmaceuticals
- ♦ Innovative technologies for biotherapies

BACCINEX SA**A2**Website: www.baccinex.com

Baccinex is the preferential and highly recognized one-stop Swiss partner (CMO) for contract manufacturing of sterile lyophilized and liquid dosage forms. We routinely supply clinical medication for phase I, II and III trials to our (bio)pharmaceutical clients.

We offer a complete service including:

- ♦ Liquid or lyophilized drug product manufacturing (under aseptic conditions, in vials or ampoules)
- ♦ Secondary packaging (randomized labeling included)
- ♦ QC analytics (physicochemical and microb).

 BIOGENOUEST**C11**Website: www.biogenouest.org

Supporting research in life and environmental sciences. Biogenouest is a Scientific Interest Group founded by : Anses, CNRS, Ifremer, Inra, Inria, Inserm, Univ. Angers, Univ. Bretagne Occ., Univ. Bretagne Sud, Univ. Nantes, Univ. Rennes1. Ministry of Research Approved. Our network brings 34 technology core facilities that deliver hands-on solutions for labs and businesses across: genomics, proteomics, functional exploration, bioimaging structural and metabolic analysis, bioinformatics.

BIONEXT**E2-D8/2**Website: www.bionext.com

Did you know: 85% of clinical failures are of biological origin and attributable to secondary targets? Classical in-silico approaches focus on the relationship between a pharmaceutical candidate and its target, but do not consider secondary interactions.

Bionext helps decipher and identifies such secondary targets based on structural knowledge of one of them within any kind of ligand-target (protein, RNA/DNA) interaction. Select the best drug candidates or repurposing possibilities, use BioSigh.

BOOST4HEALTH**D7/3**Website: www.boost4health.eu

Boost4Health provides practical and financial support to life sciences companies who wish to explore their international growth potential.

11 leading business support organisations in 7 countries across Europe have joined forces into Boost4Health project to help SME to accelerate their international growth. By sharing expertise and networks, and providing practical and financial support, the Boost4Health community helps businesses to expand into new markets within North West Europe.

**CENTRE EUROPÉEN
D'ÉTUDE DU DIABÈTE****E2-D8/8**Website: www.ceed-diabete.org

Created in 1991, the «Centre européen d'étude du Diabète» is a private translational diabetes research institute, encouraging active collaborations between clinicians and researchers, in order to develop innovative therapeutic strategies and therefor improve the patients' daily life. From its original status, the structure is a strong partner in the Scientific European community and acquired a rich portfolio of national and international collaborations from both academic and non-academic sectors.

CILOA**F1-E4/3**Website: www.ciloa.fr

Based on its disruptive technology, Ciloa helps to develop therapeutic monoclonal antibodies and vaccines. Ciloa sorts monomers, homo- or hetero-oligomers of fully native membrane proteins (GPCRs, Ion channels, Kinase receptors, viral Env proteins...) on recombinant exosomes. This tool unlocks several steps of mAb development against membrane proteins, like:

- obtaining fully native antigen,
- immunization against poor immunogens,
- robust ELISA screenings,
- easy SPR characterization.

BIOTRIAL**F3**Website: www.biotrial.com

Biotrial, leading early phase CRO, provides solutions in early development from non-clinical to phase II studies. Based in France, London, Montréal and New York, Biotrial offers tailor-made solutions for the pharmaceutical and biotech industries. Available as stand-alone or full packages, Biotrial's services line includes: Non-clinical pharmacology, Regulatory Affairs, Phase I & II Study Management, Biometrics and Medical Writing, Monitoring, Core Lab, Bioanalysis, Pharmacovigilance.

CELL&CO BIOSERVICES**A8**Website: www.cell-and-co.com

Cell&Co BioServices offers a complete one-stop-shop solution for managing biological and clinical.

The services we offer cover the following activities:

- ♦ Biobanking
 - ♦ GMP Biorepository
 - ♦ Sample processing (extraction, aliquoting, fractionation, etc.) and bioanalysis
 - ♦ Sampling kit design, production and supply;
- Cell&Co is certified ISO 9001 and NF S 96-900 and also applies the following quality standards GMP, GLP, GCP and BPR (Best Practices for Repositories).

CIDETEC NANOMEDICINE**B6**Website: www.cidetec.es/en/nanomedicine

Cidetec Nanomedicine is an institute for applied research that develops cutting-edge technology to transform it into advanced products.

Four pillars support this activity:

- ♦ Expert in technology transfer.
 - ♦ Strategic collaborations,
 - ♦ Differentiating facilities for the translation of nanomedicine
 - ♦ Direct contact with the industry and clinicians
- Our research is focused in:
- ♦ Drug-delivery via inhalation
 - ♦ Drug-delivery via skin
 - ♦ GMP Manufacturing of investigational medicinal products.

CITOLAB**E5**Website: www.citoxlab.com

With facilities located in France, Canada, Denmark and Hungary, CiToxLAB offers a comprehensive range of preclinical services to meet the needs of pharmaceutical, biotechnology, chemical, agrochemical and cosmetics companies worldwide.

CiToxLAB performs studies in general and reproductive toxicology, carcinogenicity, immunology, safety pharmacology, DMPK and bioanalysis. The group has unique expertise in areas such as inhalation, medical device, in vitro and environmental sciences.

CONFARMA**E2-D8/4**Website www.confarma.fr

Confarma is an analytical service provider for pharmaceutical, biotechnology, medical device, chemical and cosmetic industries. CONFARMA go with you for your methods development, validations and routine analysis in microbiology, biology and physico-chemistry, according to the highest standards. The site is a pharmaceutical establishment authorized by ANSM and declared compliant with GMP and GLP principles. Confarma is ISO 9001, 14001, OHSAS 18001, ISO 17025 accredited by COFRAC and FDA.

CZECHINVEST**E3**Website: www.czechinvest.org

CzechInvest, the investment and business development agency of the Ministry of Industry and Trade, works with businesses based in the Czech Republic to support their development and encourages overseas companies to look at the Czech Republic as their partner of choice. The agency helps its Czech and international customers by providing services that range from information provision and consultancy to implementation of business development programmes.

DOMAINEX**A6**Website: www.domainex.co.uk

Domainex is an integrated drug discovery service company serving pharmaceutical, biotechnology, academic and patient foundations globally. Domainex provides highly efficient scientific solutions to enable successful drug discovery programmes against a wide range of targets. Our highly experienced molecular biologists, medicinal, computation and analytical chemists have a strong success record in drug discovery, delivering on average one candidate drug every year for the past six years.

DYNACURE**E2-D8/6**Website: www.dynacure.fr

Dynacure is a biotechnology company founded in 2016 that is developing new treatments for patients affected by serious orphan disorders. In its first drug discovery program, Dynacure is focusing on Centronuclear Myopathies (CNM), a rare debilitating disease affecting children and young adults. Dynacure's Dyn101 is an antisense oligonucleotide developed in collaboration with IONIS Pharma (USA).

CYTENA GMBH**E6**Website: www.cytena.com

Cytena's single-cell printer uses an imaging system and object recognition algorithms to detect cells in a single-use dispenser cartridge. Droplets are produced similar to inkjet printing. Cells are classified in the nozzle and subsequently dispensed directly into well plates. High viability has been observed for several cell lines.

DELPHARM BIOTECH**B8**Website: www.delpharm.com

You have identified reliable biomarkers or designed mAb against a bio-target. You have developed a companion diagnostic tool: immuno assay prototype (ELISA or LFIA) for biomarkers monitoring and you are willing to find a partner to industrialize your device before commercial batch. Delpharm Biotech, as Immuno Assay contract manufacturing organization (CMO) with all the capabilities, under ISO 13485 can meet your requirements in both veterinary and human diagnostic markets.

DRUGABILIS**F1-E4/4**Website: www.drugabilis.com

DRUGABILIS is an established CRO specialized in pharmaceutical drugability of R&D compounds, including cytotoxic drugs. Our expertise includes API Solid Form Optimization (salts, polymorphs, cocrystals) & Early Formulation, ranging from animal formulation (efficacy, PK, Tox) to early clinical formulation feasibility assessment (oral low soluble, injectable, ocular, dermal, vaginal ...). We are also often engaged for trouble shooting studies on drug products facing unexplained performance issues.

EATRIS**C3B**Website: www.eatris.eu

EATRIS helps you de-risk and add value to your drug, vaccine or diagnostic development programme. We do this by providing fast, tailored access to clinical expertise and cutting-edge enabling technologies available within our 80 academic centres across Europe. Solutions are provided in the fields of advanced therapy medicinal products, biomarkers, imaging and tracing, small molecules and vaccines.

ECRINS THERAPEUTICS SERVICES

D1-C9

Website: www.ecrins-therapeutics-services.com

We offer unique services in drug discovery: cytoskeleton-related products and services. These services are intended as important filters in drug discovery and allow de-risking early-stage projects particularly in the fields of oncology and neurodegenerative-diseases. Our scientific team is dedicated to provide you answers and save you time. We are also able to offer tailor made assays from in vitro biochemistry to cell biology, in order to fully satisfy our clients' needs.

E-PHY-SCIENCE

B13

Website: www.e-phy-science.com

E-Phy-Science is a service company providing a top level expertise in in vitro and in vivo electrophysiology in rodent. Combining these two approaches, E-Phy-Science offers an 'à la carte' service which is based on reactivity and high precision. With its in Vitro platform E-Phy-Science provides field or single cell recording from acute brain slices or cell culture. With our in vivo platform, we provide field, multiunit as well as single unit recordings in freely moving or anesthetized rodents.

EU-JAPAN CENTRE FOR INDUSTRIAL COOPERATION

E7

Website: www.eu-japan.eu

The EU-Japan Centre for Industrial Cooperation is a non-profit organisation between the European Commission and the Japanese Government.

The mission of the EU-Japan Centre for Industrial Cooperation is:

- ♦ to promote all forms of industrial, trade and investment cooperation between Japan and the EU
- ♦ to strengthen the technological capabilities and the competitiveness of the European and Japanese industrial systems.

FGK CLINICAL RESEARCH GMBH

A5

Website: www.fgk-cro.com

FGK Clinical Research GmbH is a Europe-based full service Contract Research Organization with offices in Germany (HQ), Poland, Czech Republic, Hungary and UK. We provide full service for Phase I - IV clinical studies. Our international client base includes biotechnology, medical device, and pharmaceutical companies. We have all the knowledge and experience necessary to guide you through the clinical trial process, from planning and approval to the final report.

ENTERPRISE LITHUANIA

B10

Website: www.enterpriselithuania.com/enlsb2018.com

Enterprise Lithuania is a non-profit agency under Ministry of Economy established to promote entrepreneurship, support business development and foster export. Their mission is to support the establishment and development of competitive businesses in Lithuania and to foster the country's exports by facilitating cooperation with partners' networks and providing quality training, consultancy, market analysis, and business-partner search services.

ERDYN

B4

Website: www.erdyn.com

Erdyn is a pure player of innovation.

Erdyn is a leader consulting company specialized in innovation. We support our clients from strategies set up to their operational implementation to sustain growth and competitiveness through innovation.

We offer support for:

- ♦ Set up and management of collaborative projects
- ♦ Innovation marketing and business development
- ♦ Technological and scientific states of the art Technology/opportunity scouting

EURASANTÉ

D7

Website: www.lille.eurasante.com

Eurasanté is an incubator, a technology transfer facilitator and a leading cluster in the fields of biotech, nutrition and healthcare in the Northern France region. It assists French and foreign companies, entrepreneurs, scientists and clinicians with their innovation and development projects. The regional network includes around 1,000 companies working in Life Sciences and Healthcare. It benefits from an exceptional location in the heart of Europe (near Paris, London and Brussels). The Life Sciences sector in the Northern France region gathers a total of 28,000 employees. Eurasanté also promotes the Eurasanté Bio-business Park which already hosts 7 hospitals, 4 universities, 7 specialised schools, more than 150 companies and 50 laboratories.

FINDMED

D6

Website: www.findmed.fr

Findmed is a consortium of 12 Carnot institutes, which are French academic research institutions selected for their ability to set up research partnerships with the industry (from SMEs to international corporations). These institutes are devoted to health research (human or animal), as well as additional expertise in chemistry, formulation and data processing. The objective of Findmed is to facilitate the access of companies to their expertise and technological resources.

FUTURE WORLDS

B11

Website: www.futureworlds.com

Future Worlds is a startup platform and business incubator championing the innovative commercial opportunities being developed by researchers and students at the University of Southampton.

GENOSCREEN

D7/4

Website: www.genoscreen.com

GenoScreen is a French biotech company. Since 2001 GenoScreen offers innovative services and solutions that help public and private sector research groups to characterize and exploit DNA. GenoScreen works on all kinds of genomes and proposes cutting-edge technologies. Our innovation strategy has generated a stream of successful projects, including top-level expertise in the characterization of microorganisms. GenoScreen's research programs develop new applications in highly competitive fields.

HCS PHARMA

D7/6

Website: www.hcs-pharma.com

HCS Pharma is a CRO specialized in cell imaging (HCA/HCS) that offers services (phenotypic screening, efficacy and safety assays, POC) in pre-clinical in vitro research. Expertise: the development of new in vitro tests in pharmacology and their use in medium / high throughput screening in cell imaging: «High Content Analysis» (HCA) / «High Content Screening» (HCS). Its areas of expertise: neurodegenerative diseases (Parkinson, Alzheimer, ...), oncology, toxicology (hepatotoxicology ...).

IFREMER

C1

Website: www.ifremer.fr

Created by decree in 1984, the French Research Institute for Exploitation of the Sea is a public institute of industrial and commercial nature. Through studies and expert assessments, Ifremer contributes to knowledge about the oceans and their resources, the monitoring of marine and coastal zones and the sustainable development of maritime activities.

GENOSAFE

B12

Website: www.genosafe.com/fr

GenoSafe is an Unique Laboratory CRO for Gene & Cell Therapies development: at R&D, Preclinical and Clinical Development stage.

GenoSafe supports Gene and Cell Therapy product development to cure rare/degenerative diseases

- ♦ Preclinical samples analysis
- ♦ Patients samples analysis from Clinical Trial
- ♦ Immunology monitoring and ADA development

HARMONIC PHARMA

E2-D8/7

Website: www.harmonicpharma.com

Harmonic Pharma has developed a unique Pharmacological Rediscovery© platform based on polypharmacology that consists in identifying the ensemble of biological targets linked to safe drugs in order to investigate their novel therapeutic applications. The company most advanced candidate HPH112 - developed in collaboration with Institut Curie - represents a promising drug candidate for a fast and de-risked clinical development in combination with the most recent treatments e.g. immunotherapy.

ID2SANTÉ

D3

Website: www.id2sante.fr

ID2Sant  is a technology innovation centre operating in the Bretagne region (Western France). It is also the regional representative of the Atlanpole Biotherapies competitiveness cluster.

It is in close contact with regional researchers and companies from the health sector and helps forge partnerships to support R&D projects and to develop innovative health products.

INFICURE BIO

E8

Website: www.inficurebio.com

InfiCure Bio has developed a new and unique pre-clinical mouse model, the N-IF mouse, which spontaneously develops fibrosis in multiple organs.

We offer expert led, tailored, high-quality drug validation services for R&D companies and CRO's.

Our unique model offers extraordinary research advantages; is 100 percent reproducible, has a pathological progress similar to humans and displays a fibrosis preceded by inflammation.

Inficure Bio will break the status quo in anti-fibrotic drug development.

INNObIOCHIPS**D7/2**Website: www.innobiochips.fr

Innobiochips is a diagnostic company committed to propose innovative multiplex immunoassays and aims to position its technology, SirYus™, as a new standard for In Vitro Diagnostics. As of today, Innobiochips has developed and produces products dedicated to transplantation and Immunodeficiency and is partnering with several major players which decided to incorporate the technology in larger IVD application.

Innobiochips is seeking other partners with a «SirYus inside» interest.

**INSTITUT CARNOT FRANCE
FUTUR ELEVAGE****C14**Website: www.francefuturelevage.com

Carnot Institute Livestock Industry for the Future provides R&D competences to livestock sector businesses, mobilizing three main levers for multiefficient, sustainable and profitable farming: health, nutrition and breeding systems and animal genetics.

We brings together french actors from agro-veterinary research with an international visibility and R&D knowledge and expertise of three Agricultural Technical Institutes which are international leaders in the breeding services.

KITOS BIOTECH, SRLS**A7**Website: www.kitosbiotech.org

Kitos Biotech provides cell-based assay services for anticancer drug discovery research, taking advantage of cutting-edge automation systems. Kitos Biotech is an italian private company founded in 2016 by two researchers in cancer cell and molecular biology. The laboratory is located in the scientific park of Porto Conte Ricerche (Italy).

MACO PHARMA**D2**Website: www.macopharma.com

Maco Pharma is one of the key players in the medical device industry for blood transfusion, solution bags and biotherapy. Their growth has always been driven by major innovations. These innovations are the result of substantial investments in research and development, as well as cooperation with customers and partners: blood centres, research laboratories, hospitals... For each of these 3 fields, Maco Pharma offers a range of products and services for each step of the processes. With 2300 employees, 4 plants (2 in France, 1 in Poland and 1 in Tunisia) and worldwide presence in nearly 100 countries, Maco Pharma aims at offering innovative solutions and quality products to optimise therapeutic practices and make them safer.

INOVIEM SCIENTIFIC**A3**Website: www.inoviem.com

Inoviem Scientific is a Contract Research Biotech (CRB) with unique label-free technologies for the identification of clinical target(s) directly from patient samples. We currently work with big, mid and small pharma companies all over the world.

Based on our two proprietary technologies, we aim to bring the relevant information on drug's efficacy, toxicity and molecular mechanism of action, from human tissues, as early as possible to enable the pharmaceutical industry to move forward.

ITEC SERVICES**F1-E4/5**Website: www.itecservices.com

Since 1984, ITEC Services perform clinical trials for pharmaceutical, biotechnological and medical device companies: study management, regulatory management, site selection, monitoring (on site / Remote monitoring), vigilance, data-management, statistics, medical writing.

ITEC Services has been certified ISO 9001 since 1997 (version 2015) and complies with the ISO 27001.

International Business Developer: mathieu.caperad@itecservices.com

CEO: nathalie.dubon@itecservices.com

KSILINK**E2-D8/9**Website: www.ksilink.com

Ksilink's expertise lies in patient based, target free phenotypic drug discovery and preclinical development up to in vivo POC. Our ambition is to find new treatment solutions in the areas of muscular and cardiovascular diseases, neurodegenerative and psychiatric diseases. Ksilink further has launched several oncology and immune oncology projects.

Ksilink acts like a highly specialized open innovation center enabling technology transfer for academic and biotech partners.

MAGLE CHEMOSWED**B5**Website: www.maglechemoswed.com

Our Mission: We create innovative solutions to healthcare challenges.

Our vision: We combine our unique knowledge of formulating delivery systems and our drug development expertise to bring innovations from idea to Product.

We pride ourselves in coming up with elegant solutions to healthcare challenges. Whether it be developing unique products of our own or applying our expertise to advance our customers' production processes, creativity is one of our core values.

MICROSYNTH AG

B2

Website: www.microsynth.ch

As a private and independent Swiss company, Microsynth provides services related to DNA/RNA synthesis, various kinds of DNA/RNA analyses and molecular biology project outsourcing. For more than two decades, our objective has been to serve our customers by delivering products and services of the highest quality, on time and with outstanding service – and all this at competitive prices.

NEURATRIS

C3

Website: www.neuratris.com

NeurATRIS is a research infrastructure conceived to accelerate the translation of discoveries in basic research into medical innovations for the treatment of diseases of the nervous system.

NeurATRIS brings together the biggest French teams of experts such as 5 hospitals and public research institutes whose expertise and skills in neuroimaging, pharmacology and biotherapies are complementary and internationally recognized.

NeurATRIS is the French node of EATRIS-ERIC.

NUTRITION HEALTH LONGEVITY CLUSTER

D7

Website: www.nhl-cluster.com

The NHL Cluster is the only French cluster to combine Nutrition, Biotechnology and Health. The NHL Cluster focuses on the fields of prevention and treatment of life-style related diseases. We identify opportunities (technology, market, product, financial aid), we facilitate exchange between potential and existing members, we contribute to collaborative R&D projects between academia, national and international public research institutions and private companies. NHL Cluster, Your Innovation Partner.

OUEST VALORISATION

C6-B15

Website: www.ouest-valorisation.fr

Ouest Valorisation – Office of Technology Transfer (OTT) was created in the «Future Investments» project call managed by Ministry of Higher Education and Research. It aims to propose to companies attractive innovation means from the public research. Ouest Valorisation's team simplifies the access of the companies to research laboratories in order to develop good collaborative projects or to get access to high professional skills and high level scientific equipment.

NANOTRANSMED

E2-D8/3

Website: www.nanotransmed.eu

Nanotransmed enables french, german and swiss scientists to develop together applications and innovations in nanomedicine, meeting major issues regarding patients' care. The consortium focuses in particular on issues concerning early, reliable and fast diagnosis but also personalized treatment of diseases such as cancers and inflammation as well as issues regarding nosocomial infections contracted by 5% of hospitalized patients. The project is cofinanced by the Interreg VA Upper Rhine programme.

NOVA BIOMEDICAL

A4

Website: www.novabio.us/fr

Nova manufactures automated analyzers for cell culture and fermentation monitoring. Our modular BioProfile FLEX provides key chemistries and gasses and is expandable to include Cell Density and Cell Viability, Osmolality and IgG or Phosphate results with the same sample and a single data output stream. BioProfile CDV is an automated cell density/viability analyzer with a range of up to 80 million cells/mL. Stat Profile Prime is a compact high throughput, low sample volume, 9-test chemistry/gas analyzer with no maintenance cartridge technology.

OCR

D9

Website: www.oncovet-clinical-research.com

OCR is focused on comparative medicine studies of dogs with spontaneous cancers and chronic diseases, as natural animal models for assessment of drug candidates under development for Human. OCR provides to Biotech-Pharma-MedTech companies more predictive data of human diseases for a more relevant development in clinic. OCR also acts as a full vet-CRO for pilot and pivotal studies for the Vet market. OCR benefits from an internal histology/IHC platform and a canine and feline tumor biobank.

OVH DIGITAL LAUNCH PAD

E1

Website: www.ovh.com/dlp

OVH Digital Launch Pad is the startup support program of OVH, Europe's largest cloud provider. It provides innovative startups with funding and technical support from seed stage to market. Via the Digital Launch Pad, OVH will support companies with training, logistics and marketing as well as access to exclusive events and OVH's cloud infrastructure. Startups receive this assistance from early-stage until they are ready to launch publicly.

PHARMA LOGISTICS CLUB**C12**Website: www.pharmalogistics.club

The Pharma Logistics Club (PLC) is a non-profit inter-professional association, to intellectual vocation, managed by professionals belonging to health establishments and providers from all sectors, without distinction of specialties in the field of Supply Chain Pharmaceutical. Its purpose is to bring together people interested in participating to a better understanding and improvement of GDP and awareness for biotech, CRO and research institutes. International positioning, we offer conferences, technical committees, logistics site visits and online tools.

PORSOLT**D4**Website: www.porsolt.com

Porsolt, a long established, AAALAC accredited and fully GLP compliant, preclinical CRO, has been providing efficacy and safety pharmacology services for over 30 years, covering the drug development process from early screening thru regulatory submission.

Porsolt provides in vitro assays (high throughput screening, high content analysis, and high content histology) and physiopathological models in multiple species and multiple disease areas, tailored solutions and bespoke model development.

PROQINASE**C2**Website: www.proqinase.com

ProQinase is a preclinical CRO dedicated to support the development of cancer therapeutics by providing customized solutions that cover the full range of services from hit identification to preclinical testing. ProQinase's portfolio includes biochemical kinase assays, cell-based assays, and in vivo tumor models. We continuously work to extend these services and, in addition, offers custom-tailored assay development to provide state-of-the-art drug discovery service.

RD-BIOTECH**F1-E4/1**Website: www.rd-biotech.com

RD-Biotech is a French CRO offering a wide range of services and products in Biotechnology:

- Bioproduction & purification: Monoclonal antibodies (murine, rat, chimeric, humanized), Recombinant proteins, Plasmids, cells
- R&D contracts: Hybridoma development, transfection and cell lines development, Cloning and vector construction, Chimeric and humanized antibodies...
- Analytical services: Immunoassays, OCTET, bioassays platform...

FastELISA kits: Ig G quantification (mouse, human, rat).

PHENOMIN-ICS**E2-D8/5**Website: www.phenomin.fr
www.ics-mci.fr

Phenomin-ICS is a research infrastructure of excellence for translational research and functional genomics. It provides a comprehensive set of specialized services to academic and industrial users and is a major player in the European post-genomics area programs.

It ensures the generation and validation of mutant mouse and rat models «à la carte», as well as phenotypic analysis and preclinical studies covering the major physiological systems to better understand gene function and human disease.

PRECI PLATFORM**D9**Website: www.plateforme-prec.com

Since 2015, PRECI provides to Biotech-Pharma clients experimental irradiation (Megavoltage Unit - Elekta Precise) & imaging platform (CT-scan, MRI, Scintigraphy) applied to preclinical protocols (mice and rats, pigs, sheep, rabbits). PRECI also provides Histology/IHC services (VIP, embedding, microtomy, imaging tissue, specific staining - automated slide stainer - lesion scoring, morphometric analysis and immunohistochemical staining via Ventana Discovery XT).

PULSALYS**C6-B15**Website: www.pulsalys.fr

Pulsalys is a French Technology Transfer Office (TTO), created in 2013 with a public funding of 57 M€, committed in detecting high-potential research results from the laboratories of Lyon & St Etienne, and turning them into strong innovations for companies, or into high tech startup businesses.

RÉSEAU SATT**C6-B15**Website: www.satt.fr

In France, SATTs have the challenging mission to accelerate the transformation of French research into innovations. Their aim is to enhance the value and to accelerate the process of technology transfer from publically funded research toward industry. SATTs evaluate, market and license technology from French Universities and Public Research Organisations.

SATTs have become a major actor of economic development to reinforce company competitiveness, with an emphasis on SMEs and start-ups.

RHEONOVA**D1-C9**Website: www.rheonova-medical.com

Rheonova offers a new physical biomarker for drug discovery and efficacy evaluation. Our product Rheomuco and the associated services aim to provide new pharmacodynamic data during in vitro studies or clinical trials in the fields of pulmonary diseases (cystic fibrosis, COPD, asthma...). Our technology measures the viscoelasticity of mucus and deliver the physical properties of bronchial secretions. The benchmark of new molecules is performed using patient sputum or mucus obtained by cell culture.

SATT CONECTUS**C6-B15**Website: www.conectus.fr

SATT Conectus Alsace is the single entry point for companies and exclusive business partner to access all the innovations originating from public research institutions in Alsace, one of the top ranked regions in France for the excellence of research. It is also the partner of choice to access a unique and broad range of highly advanced knowhows, skills and facilities, within a favourable geographic position in the heart of Europe (Alsace borders Germany and Switzerland).

SATT GRAND EST**C6-B15**Website: www.sattge.fr

SATT Grand Est is a French governmental TTO. Our role is to identify and invest into R&D projects from French public research laboratories and transfer the resulting innovation to the industry. The scope of our activity includes: healthcare, material sciences, chemical processes, software. We also provide technical and scientific services under the trademark «Welience». Those services include genomics, lipidomics, imaging, cytometry, histology, protein engineering, bioinformatics, etc.

SATT SUD-EST**C6-B15**Website: www.sattse.com

Satt Sud Est is a private Technology Transfer Organization (TTO) with exclusive rights to source, protect, develop and license the results of research from public laboratories in the Provence-Alpes-Côte d'Azur (PACA) and Corsica french Regions. Its goal is to help companies acquire reliable technologies that are better suited to the industrial challenges they face.

SANTAKA VALLEY ASSOCIATION**B9**Website: www.santakosslenis.lt

Association Santakos Slėnis (Santaka Valley) unites and integrates activities of 4 largest research and study institutions of Kaunas : Kaunas University of Technology, Lithuanian University of Health Sciences, Vytautas Magnus University and Lithuanian Energy Institute at the science and business valley «Santaka». The aim of association is to carry out interdisciplinary scientific and applied research, to create proper conditions for high-quality research services to businesses, to coordinate.

SATT GRAND CENTRE**C6-B15**Website: www.sattgc.com

SATT Technology Transfer Organization (Center of France) organizes early detection of inventions and guarantees its exclusivity. SATT Center of France reveals the potential of future innovations for a successful transfer to business in providing financial and technical supports. Located in Clermont-Ferrand, SATT Center of France works with 6 Universities, 3 Regions, 8 Institutes of Technology and 8500 Researchers and Professors.

SATT NORD**C6-B15**Website: www.sattnord.fr

SATT Nord is a growth-generating tool for valorisation serving researchers and responding to the economic and societal needs for technology transfer. Thanks to a multidisciplinary team of professionals (experts in the various fields of research, project managers, experts in intellectual property, legal experts), SATT Nord ensures the detection of projects, their maturation and the protection of the intellectual rights and even up to their commercialisation through transfer.

SCIENCE ME UP**C10**Website: www.sciencemeup.com

Each and every project, concept or specific need is like a rocket ready to be launched. You are the captain of the spaceship and you must fulfill your mission. We are a specialized service provider in Research and Development. Whether you plan to conquer space or develop your business, our team will support your endeavours. Whatever your request, we can offer a scientific expert for service provision, event planning, recruitment, and training that will come on board to fulfill your mission.

SCIOMICS - ENABLING PRECISION MEDICINE

C15

Website: www.sciomics.de

Sciomics established a broad biomarker development pipeline for oncological indications as well as organ failure. The underlying scioDiscover platform combines a broad coverage of more than 1000 proteins including their phosphorylation status with all advantages of classical immunoassays.

Plasma, tissue, cell samples, and cerebrospinal fluid from human, mice and rat can be analysed to identify biomarkers, elucidate disease mechanisms or obtain an in-depth understanding of the underlying biology.

SIMV - FRENCH ASSOCIATION OF ANIMAL HEALTH INDUSTRY

C13

Website: www.simv.org

The French association for animal health industry (SIMV) represents and federates 39 manufacturers and marketers on the French market of medicines and reagents for pets and for farm animals.

SOLADIS

B7

Website: www.soladis.fr

Soladis is a consulting and service company specialized in data. To answer requests of data collection, analysis, and valorization, Soladis developed dedicated expertise:

- ♦ Soladis Connect, specialized in data collection through IoT, sensors and biosensors
- ♦ Soladis Statistics, to define statistical methodologies, and execute data analysis
- ♦ Soladis Digital, taking care of data science or big data projects
- ♦ Soladis Clinical Studies, full-services CRO, taking care of all or parts of clinical studies from protocol writing to publication thanks to a medical expertise.

VEOLIA WATER TECHNOLOGIES

D10

Website: www.veoliawatersti.com

Veolia Water Technologies, the expert in water cycles, provides specialist equipment for the production and supply of water to industrial companies and laboratories, in compliance with the most stringent quality of water.

Our range of Elga Veolia equipment meets all laboratory water production needs, from ultra pure water to the production of purified water for general use.

SENCET

D7/5

Website: www.sencet.fr

Sencet is a spin-off from the CNRS and relies on a bio-technologie, the Silicon Nanotweezer (SNT). The concept is based on the use of microtechnologies to measure the electrical and mechanical properties of individual cells. This type of measurement has been shown to allow the differentiation of normal and cancer cells. In the short term, Sencet products will take place in academic laboratory environment as powerful cell characterization tools. And in the middle term, Sencet will provide diagnosis tools for early detection of cancer from blood sample.

SMALTIS

F1-E4/2

Website: www.smaltis.fr

The SMALTIS compagny, specialized in biotechnologies, designs through contracted services, customized solutions in Microbiology and Molecular Biology to help laboratories with their R&D projects. Its strength relies on a qualified team with specific know-how and an ISO 9001 certification in order to provide a personalized, confidential, interactive and quality service. With a solid scientific background and a diversified and certified «toolbox», SMALTIS operates globally in R&D projects.

SYNAGING SAS

C4

Website: www.synaging.com

SynAging focuses on disease-inducing misfolded protein aggregates. Advances in neurobiology helped to understand the pivotal role of soluble prion-like misfolded protein aggregates in neurodegenerative diseases. SynAging has proprietary procedures to create aggregates with highest reproducibility. Oligomers are used in vitro and in vivo to induce neurodegeneration acutely and provide drug developers with fast access to phenotypic models mimicking the corresponding neurodegenerative disease.

VET+I FOUNDATION, SPANISH TECHNOLOGY PLATFORM FOR ANIMAL HEALTH

D5

Website: www.vetmasi.es

Vet+i Foundation is an interdisciplinary forum that integrates all relevant stakeholders from academia, research, farmers, veterinarians, industry, regulators, etc. interested in animal health in Spain.

Vet+i has been created to improve R&D in the field of animal health.

Goal: to facilitate networking and discussion in order to achieve its main goal: to enable the efficient transfer of research developed and accelerate the development and delivery of effective tools for control animal disease.

VIROSCAN3D

B1

Website: www.viroscan3d.com

ViroScan3D is a service provider company in «Genomics Analysis» for infectious diseases including Pathogen Discovery, Biomarker discovery and Biosafety. Based on a solid expertise in genomics, microgenomics, particularly in NGS and microarrays, we perform Transcriptome, Genome, Metagenome and Epigenome analysis as well as Sequencing of new virus, bacteria, fungi, viromes and microbiomes. Our services are complete, from data analysis and available from low-copy and low-integrity samples.

XPRESS BIOLOGICS

B14

Website: www.xpress-biologics.com

Xpress Biologics is a contract development organization specialized in the production of Biologics, proteins and DNA, for the therapeutic and diagnostic markets. The production scale and the quality of the biologics (R&D and GLP) are adapted for in vitro and in vivo pre-clinical validation of the biologics.

Xpress Biologics processes take into account the industrial and regulatory requirements, which greatly facilitates the transfer of the project to CMOs for the production of GMP grade material.



A BIOPHARMACEUTICAL GROUP COMMITTED TO THE LIFE

OF HUNDREDS OF THOUSANDS OF PATIENTS SUFFERING FROM SERIOUS AND OFTEN RARE DISEASES WHO ARE TREATED EACH YEAR WITH OUR BIOPHARMACEUTICALS.

The LFB Group specializes in biopharmaceuticals: plasma-derived medicinal products, recombinant proteins, monoclonal antibodies and advanced therapies.

The LFB Group manufactures its biological medicines in 5 bioproduction plants – 4 of which are in France – and markets its products in more than 40 countries.

www.groupe-lfb.com

Follow us on social networks   




ACCELERATE ACCESS TO HEALTH for people everywhere.

Our purpose is to solve the toughest problems in life science by collaborating with the global scientific community.

-  **GLOBAL**
1 global force across 66 countries
-  **EXPERTISE**
A wealth of experience in solving the toughest challenges
-  **COMPLETE**
Enhanced tools, resources and customer service

Learn more at merckgroup.com/en/expertise.html



The life science business of Merck operates as MilliporeSigma in the U.S. and Canada.
Copyright © 2017 Merck KGaA. All Rights Reserved. Merck and the Vibrant M are trademarks of Merck. All other trademarks are the property of their respective owners. 10/2017 2017 - 07570

WIN A FULL PASS FOR THE NEXT EDITION!



Biofit FOSTERING INNOVATION & TRANSFER
LILLE 2018 - FRANCE

Have a chance to win in three easy steps:

- 1 Take your picture in front of the BioFIT sponsor wall
- 2 Post it on Twitter with the hashtag: **#BioFIT2018**
- 3 Follow our account: **@BIOFIT_EVENT**

The draw will take place on 30th November 2017. The winner will be contacted by the BioFIT team.

SPONSORSHIP OPPORTUNITIES



FOR BioFIT 2018

No matter what is your business target, highlighting your visibility or connecting with key players, BioFIT has the sponsorship opportunity that suits your needs and your budget.

Here is an overview of the opportunities we can offer:

- Partnering opportunities
- Online, print and onsite visibility
- Specific sponsorship opportunities

To sponsor BioFIT next edition, on 4th and 5th December 2018 in Lille (France), please contact **Margaux Satola**: msatola@eurasante.com | +33 (0)3 59 39 01 82

Biofit FOSTERING INNOVATION & TRANSFER
STRASBOURG 2017 - FRANCE

PALAIS DE LA MUSIQUE ET DES CONGRÈS

ÉTOILE ROOM

COCKTAIL / NETWORKING / DANCING

BioParty

28TH NOVEMBER
from 6.30 pm

FOLLOW THE RHYTHM AND ENJOY YOUR NETWORKING EVENING

FEATURING DJ
VLADIMIR SPOUTNIK

Free for all BioFIT attendees

The Best Antibody Discovery Technology Is Now at Your Fingertips


TRIANNI
Exceptional Human Antibody Discovery

Trianni Mouse Antibodies are a Match for Humans

The Trianni Mouse™ platform is the only transgenic antibody discovery platform ever developed that offers the entirety of human antibody variable gene diversity in a single organism.

The V-gene segments in The Trianni Mouse are chimeric, but the variable domains of antibodies made by the mouse are entirely human. The result is human antibody leads generated from antibody genes optimized for function in the mouse. Or, in the simplest terms, The Trianni Mouse is a more human mouse.

To learn more about this innovative platform and how it can help you leave your mark on therapeutic antibody discovery and development, visit Trianni.com.



Lilly unites caring with discovery to make life better for people around the world

Lilly France 24 boulevard Vital Bouhot
CS 50004 - 92521 Neuilly sur Seine Cedex
Tél. : 01 55 49 34 34 - Fax : 01 41 44 02 47
www.lilly.fr - S.A.S. au capital de 375 713 701 €
609 849 153 R.C.S. Nanterre

Lilly

WITH THE SUPPORT OF

GOLD SPONSOR



BRONZE SPONSORS



CONTRIBUTING SPONSORS



SUPPORTERS



MEDIA PARTNERS



INSTITUTIONAL PARTNERS





Save the Date

4th & 5th
Dec. 2018

7th
edition

LILLE,
France



Biofit

FOSTERING
INNOVATION
& TRANSFER

LILLE 2018 - FRANCE

A 360° approach to source
early-stage innovations in Life Sciences

Organised by  **eurasanté**
Invest for Success



In collaboration with  **Alsace
BioValley**

Contact: Margaux Satola
msatola@eurasante.com